These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 11303071

  • 1. Pharmacological properties of (2R)-N-[1-(6-aminopyridin-2-ylmethyl)piperidin-4-yl]-2-[(1R)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetamide: a novel mucarinic antagonist with M(2)-sparing antagonistic activity.
    Hirose H, Aoki I, Kimura T, Fujikawa T, Numazawa T, Sasaki K, Sato A, Hasegawa T, Nishikibe M, Mitsuya M, Ohtake N, Mase T, Noguchi K.
    J Pharmacol Exp Ther; 2001 May; 297(2):790-7. PubMed ID: 11303071
    [Abstract] [Full Text] [Related]

  • 2. Characterization of the muscarinic receptor subtype(s) mediating contraction of the guinea-pig lung strip and inhibition of acetylcholine release in the guinea-pig trachea with the selective muscarinic receptor antagonist tripitramine.
    Roffel AF, Davids JH, Elzinga CR, Wolf D, Zaagsma J, Kilbinger H.
    Br J Pharmacol; 1997 Sep; 122(1):133-41. PubMed ID: 9298539
    [Abstract] [Full Text] [Related]

  • 3. Pharmacological properties of TD-6301, a novel bladder selective muscarinic receptor antagonist.
    McNamara A, Pulido-Rios MT, Sweazey S, Obedencio GP, Thibodeaux H, Renner T, Armstrong SR, Steinfeld T, Hughes AD, Wilson RD, Jasper JR, Mammen M, Hegde SS.
    Eur J Pharmacol; 2009 Mar 01; 605(1-3):145-52. PubMed ID: 19168050
    [Abstract] [Full Text] [Related]

  • 4. A potent, long-acting, orally active (2R)-2-[(1R)-3, 3-difluorocyclopentyl]-2-hydroxy-2-phenylacetamide: novel muscarinic M(3) receptor antagonist with high selectivity for M(3) over M(2) receptors.
    Mitsuya M, Kobayashi K, Kawakami K, Satoh A, Ogino Y, Kakikawa T, Ohtake N, Kimura T, Hirose H, Sato A, Numazawa T, Hasegawa T, Noguchi K, Mase T.
    J Med Chem; 2000 Dec 28; 43(26):5017-29. PubMed ID: 11150173
    [Abstract] [Full Text] [Related]

  • 5. Interaction of neuromuscular blocking drugs with recombinant human m1-m5 muscarinic receptors expressed in Chinese hamster ovary cells.
    Cembala TM, Sherwin JD, Tidmarsh MD, Appadu BL, Lambert DG.
    Br J Pharmacol; 1998 Nov 28; 125(5):1088-94. PubMed ID: 9846649
    [Abstract] [Full Text] [Related]

  • 6. General pharmacology of the new antimuscarinic compound vamicamide.
    Yamamoto T, Honbo T, Tokoro K, Kojimoto Y, Kodama R, Ohtsuka M, Shimomura K.
    Arzneimittelforschung; 1995 Dec 28; 45(12):1274-84. PubMed ID: 8595084
    [Abstract] [Full Text] [Related]

  • 7. Effects of imidafenacin (KRP-197/ONO-8025), a new anti-cholinergic agent, on muscarinic acetylcholine receptors. High affinities for M3 and M1 receptor subtypes and selectivity for urinary bladder over salivary gland.
    Kobayashi F, Yageta Y, Segawa M, Matsuzawa S.
    Arzneimittelforschung; 2007 Dec 28; 57(2):92-100. PubMed ID: 17396619
    [Abstract] [Full Text] [Related]

  • 8. In vivo demonstration of M3 muscarinic receptor subtype selectivity of darifenacin in mice.
    Yamada S, Maruyama S, Takagi Y, Uchida S, Oki T.
    Life Sci; 2006 Dec 14; 80(2):127-32. PubMed ID: 16996089
    [Abstract] [Full Text] [Related]

  • 9. Heterogeneity of release-inhibiting muscarinic autoreceptors in heart atria and urinary bladder: a study with M(2)- and M(4)-receptor-deficient mice.
    Zhou H, Meyer A, Starke K, Gomeza J, Wess J, Trendelenburg AU.
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Feb 14; 365(2):112-22. PubMed ID: 11819029
    [Abstract] [Full Text] [Related]

  • 10. Urinary bladder-selective action of the new antimuscarinic compound vamicamide.
    Oyasu H, Yamamoto T, Sato N, Sawada T, Ozaki R, Mukai T, Ozaki T, Nishii M, Sato H, Fujiwara T.
    Arzneimittelforschung; 1994 Nov 14; 44(11):1242-9. PubMed ID: 7848339
    [Abstract] [Full Text] [Related]

  • 11. Pharmacological characterization of a novel investigational antimuscarinic drug, fesoterodine, in vitro and in vivo.
    Ney P, Pandita RK, Newgreen DT, Breidenbach A, Stöhr T, Andersson KE.
    BJU Int; 2008 Apr 14; 101(8):1036-42. PubMed ID: 18279452
    [Abstract] [Full Text] [Related]

  • 12. Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptors.
    Shannon HE, Bymaster FP, Calligaro DO, Greenwood B, Mitch CH, Sawyer BD, Ward JS, Wong DT, Olesen PH, Sheardown MJ, Swedberg MD, Suzdak PD, Sauerberg P.
    J Pharmacol Exp Ther; 1994 Apr 14; 269(1):271-81. PubMed ID: 7909557
    [Abstract] [Full Text] [Related]

  • 13. The quaternary transformation products of N-(3-chloropropyl)-4-piperidinyl diphenylacetate and N-(2-chloroethyl)-4-piperidinyl diphenylacetate (4-DAMP mustard) have differential affinity for subtypes of the muscarinic receptor.
    Ehlert FJ, Oliff HS, Griffin MT.
    J Pharmacol Exp Ther; 1996 Feb 14; 276(2):405-10. PubMed ID: 8632303
    [Abstract] [Full Text] [Related]

  • 14. M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland.
    Ikeda K, Kobayashi S, Suzuki M, Miyata K, Takeuchi M, Yamada T, Honda K.
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Aug 14; 366(2):97-103. PubMed ID: 12122494
    [Abstract] [Full Text] [Related]

  • 15. M1 receptor agonist activity is not a requirement for muscarinic antinociception.
    Sheardown MJ, Shannon HE, Swedberg MD, Suzdak PD, Bymaster FP, Olesen PH, Mitch CH, Ward JS, Sauerberg P.
    J Pharmacol Exp Ther; 1997 May 14; 281(2):868-75. PubMed ID: 9152396
    [Abstract] [Full Text] [Related]

  • 16. Noninvasive evaluation of brain muscarinic receptor occupancy of oxybutynin, darifenacin and imidafenacin in rats by positron emission tomography.
    Yoshida A, Maruyama S, Fukumoto D, Tsukada H, Ito Y, Yamada S.
    Life Sci; 2010 Jul 31; 87(5-6):175-80. PubMed ID: 20598326
    [Abstract] [Full Text] [Related]

  • 17. Pharmacological characterization of muscarinic receptors in rabbit isolated iris sphincter muscle and urinary bladder smooth muscle.
    Choppin A, Eglen RM, Hegde SS.
    Br J Pharmacol; 1998 Jul 31; 124(5):883-8. PubMed ID: 9692772
    [Abstract] [Full Text] [Related]

  • 18. Synthesis of 1-methyl-5-(pyrazol-3- and -5-yl- and 1, 2, 4-triazol-3- and 5-yl)-1, 2, 3, 6-tetrahydropyridine derivatives and their evaluation as muscarinic receptor ligands.
    Del Giudice MR, Mustazza C, Borioni A, Gatta F, Tayebati K, Amenta F, Tucci P, Pieretti S.
    Arch Pharm (Weinheim); 2003 Jun 31; 336(3):143-54. PubMed ID: 12822179
    [Abstract] [Full Text] [Related]

  • 19. J-104129, a novel muscarinic M3 receptor antagonist with high selectivity for M3 over M2 receptors.
    Mitsuya M, Mase T, Tsuchiya Y, Kawakami K, Hattori H, Kobayashi K, Ogino Y, Fujikawa T, Satoh A, Kimura T, Noguchi K, Ohtake N, Tomimoto K.
    Bioorg Med Chem; 1999 Nov 31; 7(11):2555-67. PubMed ID: 10632066
    [Abstract] [Full Text] [Related]

  • 20. Universal template approach to drug design: polyamines as selective muscarinic receptor antagonists.
    Bolognesi ML, Minarini A, Budriesi R, Cacciaguerra S, Chiarini A, Spampinato S, Tumiatti V, Melchiorre C.
    J Med Chem; 1998 Oct 08; 41(21):4150-60. PubMed ID: 9767650
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.